Goldman Sachs Maintains Buy on Edwards Lifesciences, Lowers Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst David Roman maintains a Buy rating on Edwards Lifesciences (NYSE:EW) but lowers the price target from $107 to $91.

July 26, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs analyst David Roman maintains a Buy rating on Edwards Lifesciences but lowers the price target from $107 to $91.
The maintained Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates some short-term concerns or adjustments in valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100